{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T23:01:36Z","timestamp":1783551696340,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Canadian Consortium for the Investigation of Cannabinoids"},{"name":"Coll\u00e8ge des M\u00e9decins du Qu\u00e9bec"},{"name":"Canopy Growth Corporation"},{"name":"Alan Edwards Pain Management Unit of the McGill University Health Centre"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s40264-023-01379-0","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T18:01:35Z","timestamp":1700762495000},"page":"161-171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Descriptive Analysis of Adverse Event Reports from the Quebec Cannabis Registry"],"prefix":"10.1007","volume":"47","author":[{"given":"Yasmina","family":"Hachem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8753-2274","authenticated-orcid":false,"given":"Yola","family":"Moride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Castilloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genaro","family":"Castillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Kalaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9e","family":"N\u00e9ron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rihab","family":"Gamaoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc O.","family":"Martel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Beaulieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Ware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vigano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"issue":"3","key":"1379_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/ajag.12846","volume":"40","author":"K Chandiok","year":"2021","unstructured":"Chandiok K, Marathe S, Rooney M, et al. Cannabis and its therapeutic value in the ageing population: attitudes of health-care providers. Austral J Age. 2021;40(3):261\u201374. https:\/\/doi.org\/10.1111\/ajag.12846.","journal-title":"Austral J Age"},{"issue":"10","key":"1379_CR2","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1089\/jpm.2018.0535","volume":"22","author":"RC Costantino","year":"2019","unstructured":"Costantino RC, Felten N, Todd M, et al. A survey of hospice professionals regarding medical cannabis practices. J Palliat Med. 2019;22(10):1208\u201312. https:\/\/doi.org\/10.1089\/jpm.2018.0535.","journal-title":"J Palliat Med"},{"issue":"7","key":"1379_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022101","volume":"8","author":"EA Karanges","year":"2018","unstructured":"Karanges EA, Suraev A, Elias N, et al. Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey. BMJ Open. 2018;8(7): e022101. https:\/\/doi.org\/10.1136\/bmjopen-2018-022101.","journal-title":"BMJ Open"},{"key":"1379_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12909-015-0335-0","volume":"15","author":"D Ziemianski","year":"2015","unstructured":"Ziemianski D, Capler R, Tekanoff R, et al. Cannabis in medicine: a national educational needs assessment among Canadian physicians. BMC Med Educ. 2015;15:52. https:\/\/doi.org\/10.1186\/s12909-015-0335-0.","journal-title":"BMC Med Educ"},{"issue":"10","key":"1379_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-054044","volume":"11","author":"CM Hallinan","year":"2021","unstructured":"Hallinan CM, Gunn JM, Bonomo YA. Implementation of medicinal cannabis in Australia: innovation or upheaval? Perspectives from physicians as key informants, a qualitative analysis. BMJ Open. 2021;11(10): e054044. https:\/\/doi.org\/10.1136\/bmjopen-2021-054044.","journal-title":"BMJ Open"},{"key":"1379_CR6","doi-asserted-by":"publisher","first-page":"215013272110427","DOI":"10.1177\/21501327211042790","volume":"12","author":"R Sajdeya","year":"2021","unstructured":"Sajdeya R, Shavers A, Jean-Jacques J, et al. Practice patterns and training needs among physicians certifying patients for medical marijuana in Florida. J Prim Care Community Health. 2021;12:21501327211042790. https:\/\/doi.org\/10.1177\/21501327211042790.","journal-title":"J Prim Care Community Health"},{"key":"1379_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejim.2021.05.002","volume":"89","author":"CA MacCallum","year":"2021","unstructured":"MacCallum CA, Lo LA, Boivin M. \u201cIs medical cannabis safe for my patients?\u201d A practical review of cannabis safety considerations. Eur J Intern Med. 2021;89:10\u20138. https:\/\/doi.org\/10.1016\/j.ejim.2021.05.002.","journal-title":"Eur J Intern Med"},{"key":"1379_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejim.2018.01.004","volume":"49","author":"CA MacCallum","year":"2018","unstructured":"MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12\u20139. https:\/\/doi.org\/10.1016\/j.ejim.2018.01.004.","journal-title":"Eur J Intern Med"},{"key":"1379_CR9","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2147\/ijgm.S275049","volume":"13","author":"S Gottschling","year":"2020","unstructured":"Gottschling S, Ayonrinde O, Bhaskar A, et al. Safety considerations in cannabinoid-based medicine. Int J Gen Med. 2020;13:1317\u201333. https:\/\/doi.org\/10.2147\/ijgm.S275049.","journal-title":"Int J Gen Med"},{"issue":"4","key":"1379_CR10","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/s2215-0366(20)30074-2","volume":"7","author":"G Hindley","year":"2020","unstructured":"Hindley G, Beck K, Borgan F, et al. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. Lancet Psychiatry. 2020;7(4):344\u201353. https:\/\/doi.org\/10.1016\/s2215-0366(20)30074-2.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"1379_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/can.2016.0034","volume":"2","author":"K Iffland","year":"2017","unstructured":"Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannab Cannab Res. 2017;2(1):139\u201354. https:\/\/doi.org\/10.1089\/can.2016.0034.","journal-title":"Cannab Cannab Res"},{"issue":"24","key":"1379_CR12","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1001\/jama.2015.6358","volume":"313","author":"PF Whiting","year":"2015","unstructured":"Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456\u201373. https:\/\/doi.org\/10.1001\/jama.2015.6358.","journal-title":"JAMA"},{"issue":"1","key":"1379_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.drugalcdep.2012.12.011","volume":"131","author":"AR Winstock","year":"2013","unstructured":"Winstock AR, Barratt MJ. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend. 2013;131(1):106\u201311. https:\/\/doi.org\/10.1016\/j.drugalcdep.2012.12.011.","journal-title":"Drug Alcohol Depend"},{"key":"1379_CR14","doi-asserted-by":"publisher","DOI":"10.1089\/can.2021.0145","author":"M Ergisi","year":"2022","unstructured":"Ergisi M, Erridge S, Harris M, et al. An updated analysis of clinical outcome measures across patients from the UK Medical Cannabis Registry. Cannab Cannab Res. 2022. https:\/\/doi.org\/10.1089\/can.2021.0145.","journal-title":"Cannab Cannab Res"},{"key":"1379_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.626853","volume":"9","author":"SP Cahill","year":"2021","unstructured":"Cahill SP, Lunn SE, Diaz P, et al. Evaluation of patient reported safety and efficacy of cannabis from a survey of medical cannabis patients in Canada. Front Public Health. 2021;9: 626853. https:\/\/doi.org\/10.3389\/fpubh.2021.626853.","journal-title":"Front Public Health"},{"key":"1379_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.827849","volume":"9","author":"L Bar-Lev Schleider","year":"2022","unstructured":"Bar-Lev Schleider L, Mechoulam R, Sikorin I, et al. Adherence, safety, and effectiveness of medical cannabis and epidemiological characteristics of the patient population: a prospective study. Front Med. 2022;9: 827849. https:\/\/doi.org\/10.3389\/fmed.2022.827849.","journal-title":"Front Med"},{"issue":"1","key":"1379_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/bcp.14140","volume":"86","author":"G Crescioli","year":"2020","unstructured":"Crescioli G, Lombardi N, Bettiol A, et al. Adverse events following cannabis for medical use in Tuscany: an analysis of the Italian Phytovigilance database. Br J Clin Pharmacol. 2020;86(1):106\u201320. https:\/\/doi.org\/10.1111\/bcp.14140.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1379_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s43441-021-00346-0","volume":"56","author":"R Banerjee","year":"2022","unstructured":"Banerjee R, Erridge S, Salazar O, et al. Real world evidence in Medical Cannabis Research. Therap Innov Regul Sci. 2022;56(1):8\u201314. https:\/\/doi.org\/10.1007\/s43441-021-00346-0.","journal-title":"Therap Innov Regul Sci"},{"key":"1379_CR19","doi-asserted-by":"publisher","unstructured":"Bialas P, Fitzcharles MA, Klose P, et al. Long-term observational studies with cannabis-based medicines for chronic non-cancer pain: a systematic review and meta-analysis of effectiveness and safety. Eur J Pain (London, England). 2022. https:\/\/doi.org\/10.1002\/ejp.1957","DOI":"10.1002\/ejp.1957"},{"issue":"11","key":"1379_CR20","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1093\/pm\/pnaa163","volume":"21","author":"R Safakish","year":"2020","unstructured":"Safakish R, Ko G, Salimpour V, et al. Medical Cannabis for the management of pain and quality of life in chronic pain patients: a prospective observational study. Pain Med. 2020;21(11):3073\u201386. https:\/\/doi.org\/10.1093\/pm\/pnaa163.","journal-title":"Pain Med"},{"key":"1379_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8060807","author":"I Sagy","year":"2019","unstructured":"Sagy I, Bar-Lev Schleider L, Abu-Shakra M, et al. Safety and efficacy of medical cannabis in fibromyalgia. J Clin Med. 2019. https:\/\/doi.org\/10.3390\/jcm8060807.","journal-title":"J Clin Med"},{"key":"1379_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/510392","volume":"2013","author":"G Bar-Sela","year":"2013","unstructured":"Bar-Sela G, Vorobeichik M, Drawsheh S, et al. The medical necessity for medicinal cannabis: prospective, observational study evaluating the treatment in cancer patients on supportive or palliative care. Evid Based Complement Alternat Med eCAM. 2013;2013: 510392. https:\/\/doi.org\/10.1155\/2013\/510392.","journal-title":"Evid Based Complement Alternat Med eCAM"},{"issue":"4","key":"1379_CR23","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/acn3.51537","volume":"9","author":"O Devinsky","year":"2022","unstructured":"Devinsky O, Marmanillo A, Hamlin T, et al. Observational study of medical marijuana as a treatment for treatment-resistant epilepsies. Ann Clin Transl Neurol. 2022;9(4):497\u2013505. https:\/\/doi.org\/10.1002\/acn3.51537.","journal-title":"Ann Clin Transl Neurol"},{"key":"1379_CR24","unstructured":"https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-medication\/cannabis\/information-medical-practitioners\/information-health-care-professionals-cannabis-cannabinoids.html. Accessed 24 July 2023."},{"key":"1379_CR25","unstructured":"Quebec Medical College. Guidelines concerning the prescription of dried cannabis for medical purposes. Quebec: Quebec Medical College, 2014"},{"key":"1379_CR26","doi-asserted-by":"publisher","DOI":"10.1089\/can.2022.0041","author":"A Vigano","year":"2022","unstructured":"Vigano A, Moride Y, Hachem Y, Canac-Marquis M, Gamaoun R, Kalaba M, Martel MO, Perez J, N\u00e9ron A, Beaulieu P, Desroches J. The Quebec Cannabis Registry: investigating the safety and effectiveness of medical cannabis. Cannab Cannab Res. 2022. https:\/\/doi.org\/10.1089\/can.2022.0041.","journal-title":"Cannab Cannab Res"},{"key":"1379_CR27","unstructured":"Health Canada. Information for Health Care Practitioners\u2014Cannabis (marihuana, marijuana) and the cannabinoids. In: Canada H, ed. Internet: Health Canada, 2018."},{"key":"1379_CR28","unstructured":"College of Family Physicians of Canada. Authorizing dried cannabis for chronic pain or anxiety: preliminary guidance from the College of Family Physicians of Canada. Mississauga: College of Family Physicians of Canada, 2014."},{"key":"1379_CR29","unstructured":"U.S. Food and Drug Administration. What is a serious adverse event? In: FDA Website. FDA. 2016. https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event. Accessed 03 Aug 2022."},{"issue":"2","key":"1379_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109\u201317. https:\/\/doi.org\/10.2165\/00002018-199920020-00002.","journal-title":"Drug Saf"},{"issue":"5","key":"1379_CR31","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/j.pain.0000000000002463","volume":"163","author":"J Aviram","year":"2022","unstructured":"Aviram J, Lewitus GM, Vysotski Y, et al. Sex differences in medical cannabis-related adverse effects. Pain. 2022;163(5):975\u201383. https:\/\/doi.org\/10.1097\/j.pain.0000000000002463.","journal-title":"Pain"},{"issue":"1","key":"1379_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/npp.2017.140","volume":"43","author":"ZD Cooper","year":"2018","unstructured":"Cooper ZD, Craft RM. Sex-dependent effects of cannabis and cannabinoids: a translational perspective. Neuropsychopharmacology. 2018;43(1):34\u201351. https:\/\/doi.org\/10.1038\/npp.2017.140.","journal-title":"Neuropsychopharmacology"},{"key":"1379_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejim.2018.01.019","volume":"49","author":"R Abuhasira","year":"2018","unstructured":"Abuhasira R, Schleider LB-L, Mechoulam R, et al. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur J Internal Med. 2018;49:44\u201350. https:\/\/doi.org\/10.1016\/j.ejim.2018.01.019.","journal-title":"Eur J Internal Med."},{"issue":"1","key":"1379_CR34","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41598-018-37570-y","volume":"9","author":"L Bar-Lev Schleider","year":"2019","unstructured":"Bar-Lev Schleider L, Mechoulam R, Saban N, et al. Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Sci Rep. 2019;9(1):200. https:\/\/doi.org\/10.1038\/s41598-018-37570-y.","journal-title":"Sci Rep"},{"key":"1379_CR35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejim.2018.01.023","volume":"49","author":"L Bar-Lev Schleider","year":"2018","unstructured":"Bar-Lev Schleider L, Mechoulam R, Lederman V, et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med. 2018;49:37\u201343. https:\/\/doi.org\/10.1016\/j.ejim.2018.01.023.","journal-title":"Eur J Intern Med"},{"key":"1379_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26206257","author":"A Bennici","year":"2021","unstructured":"Bennici A, Mannucci C, Calapai F, et al. Safety of medical cannabis in neuropathic chronic pain management. Molecules (Basel, Switzerland). 2021. https:\/\/doi.org\/10.3390\/molecules26206257.","journal-title":"Molecules (Basel, Switzerland)"},{"key":"1379_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2020.102592","volume":"56","author":"Y Zolotov","year":"2021","unstructured":"Zolotov Y, Eshet L, Morag O. Preliminary assessment of medical cannabis consumption by cancer survivors. Complement Ther Med. 2021;56: 102592. https:\/\/doi.org\/10.1016\/j.ctim.2020.102592.","journal-title":"Complement Ther Med"},{"issue":"11","key":"1379_CR38","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1097\/meg.0000000000001565[publishedOnlineFirst:2019\/10\/01]","volume":"31","author":"T Naftali","year":"2019","unstructured":"Naftali T, Bar-Lev Schleider L, Sklerovsky Benjaminov F, et al. Medical cannabis for inflammatory bowel disease: real-life experience of mode of consumption and assessment of side-effects. Eur J Gastroenterol Hepatol. 2019;31(11):1376\u201381. https:\/\/doi.org\/10.1097\/meg.0000000000001565[publishedOnlineFirst:2019\/10\/01].","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"12","key":"1379_CR39","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.jpain.2015.07.014","volume":"16","author":"MA Ware","year":"2015","unstructured":"Ware MA, Wang T, Shapiro S, et al. Cannabis for the management of pain: assessment of safety study (COMPASS). J Pain. 2015;16(12):1233\u201342. https:\/\/doi.org\/10.1016\/j.jpain.2015.07.014.","journal-title":"J Pain"},{"issue":"3","key":"1379_CR40","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/17512433.2023.2183841","volume":"16","author":"F Olsson","year":"2023","unstructured":"Olsson F, Erridge S, Tait J, Holvey C, et al. An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry. Expert Rev Clin Pharmacol. 2023;16(3):257\u201366. https:\/\/doi.org\/10.1080\/17512433.2023.2183841.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"1379_CR41","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s12529-017-9686-8","volume":"25","author":"JA Sturgeon","year":"2018","unstructured":"Sturgeon JA, Hah JM, Sharifzadeh Y, et al. Predictors of daily pain medication use in individuals with recurrent back pain. Int J Behav Med. 2018;25(2):252\u20138. https:\/\/doi.org\/10.1007\/s12529-017-9686-8.","journal-title":"Int J Behav Med"},{"issue":"3","key":"1379_CR42","doi-asserted-by":"publisher","first-page":"406","DOI":"10.15288\/jsad.2015.76.406","volume":"76","author":"BE Perron","year":"2015","unstructured":"Perron BE, Bohnert K, Perone AK, et al. Use of prescription pain medications among medical cannabis patients: comparisons of pain levels, functioning, and patterns of alcohol and other drug use. J Stud Alcohol Drugs. 2015;76(3):406\u201313. https:\/\/doi.org\/10.15288\/jsad.2015.76.406.","journal-title":"J Stud Alcohol Drugs"},{"issue":"1","key":"1379_CR43","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/1471-2474-10-137","volume":"10","author":"R Blamey","year":"2009","unstructured":"Blamey R, Jolly K, Greenfield S, et al. Patterns of analgesic use, pain and self-efficacy: a cross-sectional study of patients attending a hospital rheumatology clinic. BMC Musculoskelet Disord. 2009;10(1):137. https:\/\/doi.org\/10.1186\/1471-2474-10-137.","journal-title":"BMC Musculoskelet Disord"},{"key":"1379_CR44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/00003643-200219261-00003","volume":"19","author":"D Isacson","year":"2002","unstructured":"Isacson D, Bingefors K. Epidemiology of analgesic use: a gender perspective. Eur J Anaesthesiol EJA. 2002;19:5\u201315.","journal-title":"Eur J Anaesthesiol EJA"},{"issue":"11","key":"1379_CR45","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/bcp.13710","volume":"84","author":"CJ Lucas","year":"2018","unstructured":"Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84(11):2477\u201382. https:\/\/doi.org\/10.1111\/bcp.13710.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01379-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-023-01379-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01379-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T09:10:53Z","timestamp":1706433053000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-023-01379-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1379"],"URL":"https:\/\/doi.org\/10.1007\/s40264-023-01379-0","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,23]]},"assertion":[{"value":"30 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was supported by grants from the Canadian Consortium for the Investigation of Cannabinoids, the Coll\u00e8ge des M\u00e9decins du Qu\u00e9bec (CMQ) and unrestricted grants from several licensed cannabis producers (Bedrocan, Mettrum and Tweed; these three companies merged during the study conduct into one company called Canopy Growth Corporation) and nowadays Spectrum Therapeutics is the medical division of Canopy Growth\u00a0Corporation). Funding for data analysis was received from the Alan Edwards Pain Management Unit of the McGill University Health Centre. Cedars Cancer Foundation and Rossy Cancer Network supported the Medical Cannabis Program in Oncology of the McGill University Health Center, which provided most data on oncology patients to the Quebec Cannabis Registry (QCR). No funding agency had input into the design and conduct of the QCR, although the CMQ was present at development meetings.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"YM, AMC, and GC are employees of YolaRX Consultants, which provides consulting services to the pharmaceutical industry and cannabis manufacturers on topics unrelated to this research. MW and MK were\u00a0 employees of Canopy Growth Corporation (MW:\u00a02018\u20132022 and MK: 2019\u20132023). AN is a consultant on request in medical cannabis-related pharmacological assessments and needs for injured workers (Bureau d'\u00e9valuation m\u00e9dicale). AV was a member of the Clinical Advisory Board for Tilray, Canopy Growth Corporation, Syqe and EmpowerPharm. Until March 2020, AV was the Research Director of Sant\u00e9 Cannabis, Montreal, Canada. MM, PB, RG, and YH have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No additional data available.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"There is no code available.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"AV, PB, and\u00a0MW,\u00a0contributed to the registry design. YM designed the safety analysis and\u00a0AMC did the data analysis. All authors contributed to the manuscript preparation. All authors read and approved the final manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors contributions"}},{"value":"The project was initially approved by the central research ethics committee of the Ministry of Health and Social Services (CCER) of Quebec, which monitored the project for the private clinics and the participating institutions of the health and social services network. On 03 May 2019, the McGill University Health Centre Research Ethics Board took over the role of the CCER for the QCR.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided informed consent to participate in the registry. Information is anonymous and only aggregate data are reported.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}